VEMLIDY Exclusivity Summary
Summary
FDA posted an exclusivity summary for VEMLIDY (tenofovir alafenamide), a hepatitis B treatment marketed by Gilead Sciences. The document was filed to the regulatory docket on April 21 and is accessible via regulations.gov. The posted content consists of a download link to the PDF; no substantive exclusivity determination text is visible in the source.
About this source
GovPing monitors Regs.gov: Food and Drug Administration for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 367 changes logged to date.
What changed
FDA posted a docket entry titled VEMLIDY Exclusivity Summary to regulations.gov. The source consists solely of a PDF download link; no substantive text from the exclusivity determination is visible in the source record. The docket number FDA-2026-P-4112 indicates a citizen petition or request rather than a self-initiated FDA rulemaking.
Affected parties — specifically Gilead Sciences and any competitors evaluating generic-entry timelines for tenofovir alafenamide — should download the PDF directly from the regulations.gov link to review the actual exclusivity findings. The source record alone does not disclose exclusivity periods, triggering studies, or pediatric study requirements.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.